US › Healthcare

Korro Bio, Inc. (KRRO)

US · Healthcare · Biotechnology

$11.35+5.68%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-19.6M
Profit YoY
+16.1%
EPS
$-1.69
EPS estimate
$-1.98

EPS came in at -1.69 against a street estimate of -1.98 — a beat of 14.7%.

Key statistics

Market cap
$149.6M
Forward P/E
0.0
P/B
1.25
Book value
$8.29
EPS (TTM)
$-11.68
52-week high
$55.89
52-week low
$5.20
50-day MA
$12.19
200-day MA
$14.01
Beta
2.11

Analyst view

Analysts rate Korro Bio, Inc. a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $20.00.

Shareholding

Insiders
1.00%
Institutions
97.01%

Largest institutional holders

FundStake
Lynx1 Capital Management, LP10.67%
NEA Management Company, LLC9.00%
Atlas Venture Life Science Advisors, LLC7.88%
Balyasny Asset Management LLC7.21%
VR Adviser, LLC7.00%
Affinity Asset Advisors, LLC4.90%
Nantahala Capital Management, LLC4.58%
ADAR1 Capital Management LLC3.74%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Korro Bio, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.